15 Mar 2018
Full year results highlight strong bioprocessing revenue growth
Oxford BioMedica’s full year results highlight the continued step up in bioprocessing and commercial development income, increasing 36% in the year, as the facilities operate close to capacity. The group announced on Friday that it had raised £20.5m to fund the expansion of its bioprocessing facilities as it continues to focus on establishing additional deals with its LentiVector® platform (as evident by the most recent deal with Bioverativ). The group’s partnered product pipeline continues to p ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Full year results highlight strong bioprocessing revenue growth
Oxford BioMedica plc (OXB:LON) | 218 7.6 1.6% | Mkt Cap: 218.3m
- Published:
15 Mar 2018 -
Author:
Sheena Berry -
Pages:
4
Oxford BioMedica’s full year results highlight the continued step up in bioprocessing and commercial development income, increasing 36% in the year, as the facilities operate close to capacity. The group announced on Friday that it had raised £20.5m to fund the expansion of its bioprocessing facilities as it continues to focus on establishing additional deals with its LentiVector® platform (as evident by the most recent deal with Bioverativ). The group’s partnered product pipeline continues to p ....